Premium
Canrenoate in normal man
Author(s) -
Mroczek William J.,
Davidov Michael E.,
Horoschak Alan,
Finnerty Frank A.
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1974162336
Subject(s) - spironolactone , diuretic , medicine , mineralocorticoid , blood pressure , endocrinology , heart rate , aldosterone , anesthesia
Canrenoate, which has mineralocorticoid blocking activity, was evaluated in 3 normal subiects. The drug was administered by intravenous iniection twice daily for 7 days after 3 days of placebo. Loss of body weight and changes in serum and urine electrolytes were consistent with mineralocorticoid blocking activity. Canrenoate did not appear to have any effect on arterial blood pressure or cardiac output. A small increase in resting heart rate was demonstrated in 2 of the 3 patients, but this was thought to be secondary to volume depletion due to a diuretic action. A transient cardiac arrhythmia was noted in one sub;ect and was unexplained on the basis of serum electrolytes or plasma drug level. The only advantage of canrenoate over spironolactone appeared to be the parenteral administration.